KARD
Kardigan, Inc.
Price Chart
Latest Quote
$22.58
+0.55 (+2.50%)
Current Price
| Previous Close | $22.03 |
| Open | $22.28 |
| Day High | $23.88 |
| Day Low | $21.19 |
| Volume | 296,801 |
Stock Information
| Shares Outstanding | 89.34M |
| Total Debt | $13.92M |
| Cash Equivalents | $287.11M |
| Net Income | $-229.99M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.02B |
| EPS (TTM) | $-2.57 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.78B |
| Income | $-229.99M |
| Cash/sh | $3.21 |
| Employees | 241 |
Financial Ratios
| Quick Ratio | 9.07 |
| Current Ratio | 9.41 |
| Debt/Eq | 4.69 |
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
| Recommendation | none |
Technical Indicators
| Shares Float | 38.13M |
Performance History
| YTD | +2.64% |
| 10 Years | +2.64% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $22.58 | 298,900 |
| 2026-06-24 | $22.03 | 472,300 |
| 2026-06-23 | $22.24 | 548,400 |
| 2026-06-22 | $22.77 | 922,100 |
| 2026-06-18 | $22.00 | 5,844,400 |
About Kardigan, Inc.
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The company incorporates Prolaio's cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence. The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments. Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector. The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024. The company was founded in 2023 and is based in Princeton, New Jersey.
đ° Latest News
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $0 | $0 |
| Operating Revenue | $0 | $0 |
| Expenses | ||
| Total Expenses | $201,836,000 | $96,656,000 |
| Other Income Expense | $-1,467,000 | $6,705,000 |
| Other Non Operating Income Expenses | $-7,799,000 | $-46,000 |
| Net Non Operating Interest Income Expense | $6,850,000 | $1,293,000 |
| Operating Expense | $201,836,000 | $96,656,000 |
| General And Administrative Expense | $48,750,000 | $12,362,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-191,941,000 | $-88,658,000 |
| Net Interest Income | $6,850,000 | $1,293,000 |
| Interest Income | $6,850,000 | $1,293,000 |
| Normalized Income | $-198,127,571 | $-95,409,000 |
| Net Income From Continuing And Discontinued Operation | $-191,941,000 | $-88,658,000 |
| Total Operating Income As Reported | $-201,836,000 | $-96,656,000 |
| Net Income Common Stockholders | $-191,941,000 | $-88,658,000 |
| Net Income | $-191,941,000 | $-88,658,000 |
| Net Income Including Noncontrolling Interests | $-191,941,000 | $-88,658,000 |
| Net Income Continuous Operations | $-191,941,000 | $-88,658,000 |
| Pretax Income | $-196,453,000 | $-88,658,000 |
| Special Income Charges | $5,232,000 | $0 |
| Interest Income Non Operating | $6,850,000 | $1,293,000 |
| Operating Income | $-201,836,000 | $-96,656,000 |
| Per Share | ||
| Diluted EPS | $-5.04 | - |
| Basic EPS | $-5.04 | $-2.27 |
| Other | ||
| Tax Effect Of Unusual Items | $145,429 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-202,321,000 | $-103,061,000 |
| Total Unusual Items | $6,332,000 | $6,751,000 |
| Total Unusual Items Excluding Goodwill | $6,332,000 | $6,751,000 |
| Reconciled Depreciation | $5,847,000 | $346,000 |
| EBITDA (Bullshit earnings) | $-195,989,000 | $-96,310,000 |
| EBIT | $-201,836,000 | $-96,656,000 |
| Diluted Average Shares | $38,109,593 | - |
| Basic Average Shares | $38,109,593 | $39,114,301 |
| Diluted NI Availto Com Stockholders | $-191,941,000 | $-88,658,000 |
| Tax Provision | $-4,512,000 | $0 |
| Restructuring And Mergern Acquisition | $-5,232,000 | $0 |
| Gain On Sale Of Security | $1,100,000 | $6,751,000 |
| Research And Development | $153,086,000 | $84,294,000 |
| Selling General And Administration | $48,750,000 | $12,362,000 |
| Other Gand A | $15,938,000 | $6,045,000 |
| Salaries And Wages | $32,812,000 | $6,317,000 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-273,560,000 | $-83,194,000 |
| Total Assets | $390,942,000 | $63,526,000 |
| Total Non Current Assets | $45,589,000 | $13,208,000 |
| Other Non Current Assets | $4,130,000 | $2,075,000 |
| Goodwill And Other Intangible Assets | $23,225,000 | $0 |
| Other Intangible Assets | $23,225,000 | - |
| Current Assets | $345,353,000 | $50,318,000 |
| Other Current Assets | $9,868,000 | $916,000 |
| Cash Cash Equivalents And Short Term Investments | $335,485,000 | $49,402,000 |
| Cash And Cash Equivalents | $108,989,000 | $49,402,000 |
| Debt | ||
| Total Debt | $13,832,000 | $9,544,000 |
| Long Term Debt And Capital Lease Obligation | $10,689,000 | $8,764,000 |
| Current Debt And Capital Lease Obligation | $3,143,000 | $780,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $641,277,000 | $146,720,000 |
| Total Non Current Liabilities Net Minority Interest | $603,741,000 | $138,435,000 |
| Other Non Current Liabilities | $6,902,000 | $9,649,000 |
| Current Liabilities | $37,536,000 | $8,285,000 |
| Other Current Liabilities | $5,766,000 | $263,000 |
| Payables And Accrued Expenses | $28,627,000 | $7,242,000 |
| Payables | $7,990,000 | $3,861,000 |
| Accounts Payable | $7,990,000 | $3,861,000 |
| Equity | ||
| Common Stock Equity | $-250,335,000 | $-83,194,000 |
| Total Equity Gross Minority Interest | $-250,335,000 | $-83,194,000 |
| Stockholders Equity | $-250,335,000 | $-83,194,000 |
| Gains Losses Not Affecting Retained Earnings | $63,000 | $0 |
| Other Equity Adjustments | $63,000 | - |
| Retained Earnings | $-281,089,000 | $-89,148,000 |
| Preferred Securities Outside Stock Equity | $586,150,000 | $120,022,000 |
| Other | ||
| Tangible Book Value | $-273,560,000 | $-83,194,000 |
| Invested Capital | $-250,335,000 | $-83,194,000 |
| Working Capital | $307,817,000 | $42,033,000 |
| Capital Lease Obligations | $13,832,000 | $9,544,000 |
| Total Capitalization | $-250,335,000 | $-83,194,000 |
| Additional Paid In Capital | $30,691,000 | $5,954,000 |
| Capital Stock | $0 | $0 |
| Common Stock | $0 | $0 |
| Long Term Capital Lease Obligation | $10,689,000 | $8,764,000 |
| Current Capital Lease Obligation | $3,143,000 | $780,000 |
| Current Accrued Expenses | $20,637,000 | $3,381,000 |
| Net PPE | $18,234,000 | $11,133,000 |
| Accumulated Depreciation | $-1,013,000 | $-11,000 |
| Gross PPE | $19,247,000 | $11,144,000 |
| Leases | $396,000 | $0 |
| Construction In Progress | $370,000 | $528,000 |
| Other Properties | $16,992,000 | $10,616,000 |
| Machinery Furniture Equipment | $1,489,000 | $0 |
| Properties | $0 | $0 |
| Other Short Term Investments | $226,496,000 | $0 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-157,696,000 | $-55,244,000 |
| Operating Activities | ||
| Operating Cash Flow | $-151,056,000 | $-18,825,000 |
| Cash Flow From Continuing Operating Activities | $-150,952,000 | $-18,836,000 |
| Operating Gains Losses | $14,360,000 | - |
| Investing Activities | ||
| Capital Expenditure | $-6,640,000 | $-36,419,000 |
| Investing Cash Flow | $-237,037,000 | $-36,419,000 |
| Cash Flow From Continuing Investing Activities | $-237,037,000 | $-36,419,000 |
| Financing Activities | ||
| Issuance Of Capital Stock | $453,608,000 | $102,044,000 |
| Financing Cash Flow | $447,807,000 | $105,009,000 |
| Cash Flow From Continuing Financing Activities | $447,807,000 | $105,009,000 |
| Net Other Financing Charges | $-6,362,000 | - |
| Net Preferred Stock Issuance | $453,608,000 | $102,044,000 |
| Preferred Stock Issuance | $453,608,000 | $102,044,000 |
| Other | ||
| Issuance Of Debt | $0 | $600,000 |
| End Cash Position | $109,529,000 | $49,815,000 |
| Beginning Cash Position | $49,815,000 | $50,000 |
| Changes In Cash | $59,714,000 | $49,765,000 |
| Proceeds From Stock Option Exercised | $561,000 | $2,365,000 |
| Net Issuance Payments Of Debt | $0 | $600,000 |
| Net Long Term Debt Issuance | $0 | $600,000 |
| Long Term Debt Issuance | $0 | $600,000 |
| Net Investment Purchase And Sale | $-226,436,000 | $0 |
| Sale Of Investment | $17,000,000 | $0 |
| Purchase Of Investment | $-243,436,000 | $0 |
| Net Business Purchase And Sale | $-3,961,000 | $0 |
| Purchase Of Business | $-3,961,000 | $0 |
| Net Intangibles Purchase And Sale | $-1,565,000 | $-34,615,000 |
| Purchase Of Intangibles | $-1,565,000 | $-34,615,000 |
| Net PPE Purchase And Sale | $-5,075,000 | $-1,804,000 |
| Purchase Of PPE | $-5,075,000 | $-1,804,000 |
| Change In Working Capital | $6,427,000 | $4,852,000 |
| Change In Other Current Liabilities | $103,000 | $70,000 |
| Change In Other Current Assets | $-3,532,000 | $21,000 |
| Change In Payables And Accrued Expense | $16,997,000 | $5,677,000 |
| Change In Accrued Expense | $15,238,000 | $3,619,000 |
| Change In Payable | $1,759,000 | $2,058,000 |
| Change In Account Payable | $1,759,000 | $2,058,000 |
| Change In Prepaid Assets | $-7,141,000 | $-916,000 |
| Other Non Cash Items | $2,910,000 | $58,681,000 |
| Stock Based Compensation | $15,853,000 | $5,954,000 |
| Deferred Tax | $-4,512,000 | $0 |
| Deferred Income Tax | $-4,512,000 | $0 |
| Depreciation Amortization Depletion | $5,847,000 | $346,000 |
| Depreciation And Amortization | $5,847,000 | $346,000 |
| Amortization Cash Flow | $3,300,000 | $0 |
| Amortization Of Intangibles | $3,300,000 | $0 |
| Depreciation | $2,547,000 | $346,000 |
| Pension And Employee Benefit Expense | $14,360,000 | $0 |
| Net Income From Continuing Operations | $-191,941,000 | $-88,658,000 |
Fetched: 2026-06-19